|
Recruiting
|
NCT05766410 -
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
|
Phase 2 |
|
Recruiting
|
NCT05467891 -
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
|
Phase 2 |
|
Active, not recruiting
|
NCT04997941 -
Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
|
Phase 2 |
|
Recruiting
|
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 |
|
Active, not recruiting
|
NCT05064085 -
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
|
Phase 1 |
|
Recruiting
|
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 |
|
Not yet recruiting
|
NCT05122377 -
RWE About QOL and Compliance of Patients With OFS in China
|
|
|
Not yet recruiting
|
NCT04891731 -
Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
|
|
|
Terminated
|
NCT04942054 -
A Study in Patients With Advanced Breast Cancer
|
Phase 1 |
|
Recruiting
|
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 |
|
Suspended
|
NCT05503108 -
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
|
Phase 3 |
|
Recruiting
|
NCT04925284 -
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
|
Phase 1 |
|
Withdrawn
|
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 |
|
Completed
|
NCT01177397 -
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
|
Phase 1/Phase 2 |
|
Active, not recruiting
|
NCT05165225 -
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
|
Phase 2 |
|
Recruiting
|
NCT05573126 -
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT05608252 -
VS-6766+Abema+Fulv in Met HR+/HER- BC
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 |
|
Recruiting
|
NCT05115474 -
Study of Screening Brain MRIs in Stage IV Breast Cancer
|
|
|
Recruiting
|
NCT05524584 -
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
|
Phase 2 |